Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB Pharma unveils strategic development plans

UCB Pharma unveils strategic development plans

9th January 2009

UCB Pharma has agreed a strategic partnership with Wilex that will see the companies work together to develop new diagnostic agents and drugs for the treatment of cancer.

As part of the deal, UCB’s two small-molecule programmes and three antibody programmes will be developed by Wilex as part of a bid to commercialise the firm’s preclinical oncology portfolio.

It has also been advised that UCB will make an initial investment of ten million euros on closure of the initiative and will see another payment of the same amount once applications for phase I trials are submitted and human testing begins.

These milestone payments are expected to begin within approximately 12 months of Wilex closing the aforementioned programmes.

Dr Melanie Lee, UCB’s executive vice-president, said the strategic partnership would be an ideal opportunity to build on the potential of its preclinical oncology programmes.

Chairman of Wilex’s executive management board, Professor Olaf G Wilhelm, added the move would be beneficial to both companies.

“We have gained in UCB, not only an important development partner, but also a strong strategic investor which will help to further the development of our company.”

Last year, UCB announced that a partnership with Jazz Pharmaceuticals had resulted in positive phase III trials for its sodium oxybate-based fibromyalgia treatment.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.